Wade Thomas Iams, MD

Articles

Dr Iams on the Impact of Adagrasib on Patient Outcomes in KRAS G12C–Mutant NSCLC

October 18th 2023

Wade T. Iams, MD, discusses the impact of adagrasib on the treatment of patients with KRAS G12C-mutant NSCLC in the second line, as well as its integration into clinical practice.

Dr Iams on the Effect of the FLAURA2 Trial in EGFR-Mutant NSCLC

October 12th 2023

Wade T. Iams, MD, discusses the impact of the phase 3 FLAURA2 trial in patients with EGFR-mutant non–small cell lung cancer, highlighting the notable improvements in progression-free survival that the approach elicits.

Exploring TROP2 Expression in Patients with NSCLC

June 16th 2023

Martin Dietrich, MD, PhD, and Wade Thomas Iams, MD, review the value of TROP2 as a target in patients with NSCLC.

Targeting HER3 in EGFR-Mutant NSCLC

June 16th 2023

Experts review data on treatment with HER3-directed agents in NSCLC for patients with EGFR mutations.

HER2-Directed Agents in NSCLC

June 9th 2023

Dr Wade Thomas Iams explains how trastuzumab deruxtecan became the standard-of-care for HER2-mutated non-small cell lung cancer.

Targeting CEACAM5 in Patients with Non-Small Cell Lung Cancer

June 9th 2023

Martin Dietrich, MD, PhD, details the molecular target CEACAM5 and its use in the treatment of patients with non-small cell lung cancer.

ADCs in Development for the Treatment of Lung Cancer

June 2nd 2023

Drs Martin Dietrich and Wade Thomas Iams discuss the differences between the targets, payloads, and linker technologies of the antibody drug conjugates in development for lung cancer.

Overview of Antibody Drug Conjugates in Lung Cancer

June 2nd 2023

Wade Thomas Iams, MD, provides an overview of antibody drug conjugates in the treatment of patients with lung cancer, including challenges and impact on clinical practice.